Market Research Logo

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2018

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2018

Summary

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms


Introduction
Global Markets Direct Report Coverage
Calcitonin Gene Related Peptide (CGRP) - Overview
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
Alder Biopharmaceuticals Inc
Eli Lilly and Co
Serometrix LLC
Teva Pharmaceutical Industries Ltd
Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
AFAP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit IL23 and CGRP for Autoimmune Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eptinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fremanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NOXL-41 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CGRP for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Calcitonin Gene Related Peptide (CGRP) - Dormant Products
Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
Featured News & Press Releases
Jun 29, 2018: Alder BioPharmaceuticals Presents New One-Year Data for Eptinezumab from PROMISE 1 Phase 3 Trial Demonstrating Long-Term Efficacy in Episodic Migraine
Jun 29, 2018: Alder BioPharmaceuticals Presents New Six-Month Data for Eptinezumab Demonstrating Improvement in Efficacy in PROMISE 2 Phase 3 Trial for Chronic Migraine
Jun 28, 2018: Teva to Present New Fremanezumab Data, Including Long-Term Data, at the American Headache Society’s 60th Annual Scientific Meeting
Jun 27, 2018: AHS 2018: Lilly Emgality (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX (onabotulinumtoxinA)
Jun 20, 2018: Alder BioPharmaceuticals to Present New Data Further Highlighting Eptinezumab's Efficacy Profile for Migraine Prevention at American Headache Society Meeting
Jun 15, 2018: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
Jun 07, 2018: Alder BioPharmaceuticals Names Robert W. Azelby President and Chief Executive Officer
May 23, 2018: Teva Confirms September PDUFA Date for Fremanezumab
May 18, 2018: Teva Pharmaceutical Industries Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
May 15, 2018: Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association
Apr 25, 2018: Alder BioPharmaceuticals New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals (Up to 32.5 days) and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine
Apr 24, 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies
Apr 24, 2018: Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine
Apr 23, 2018: Alder BioPharmaceuticals Appoints Eric Carter, Ph.D., M.D., as Interim Chief Medical Officer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Alder Biopharmaceuticals Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Serometrix LLC, H2 2018
Pipeline by Teva Pharmaceutical Industries Ltd, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018
List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report